Key facts
- This page summarizes Lance Alstodt's Form 4 filing for BioRestorative Therapies, Inc. (BRTX).
- 2 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 20 Oct 2025, 08:02.
Lance Alstodt - 06 Oct 2025 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)
- Reporting relationship
- President, CEO, COB, Director, 10%+ Owner
- Issuer ticker
- BRTX
- Reported as of
- 06 Oct 2025
- Net transaction value
- +$25,000
- SEC form
- 4
- Accepted by SEC
- 20 Oct 2025, 08:02:27 UTC
- Prior SEC filing
- 19 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lance Alstodt
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Lance Alstodt filed Form 4 for BioRestorative Therapies, Inc. (BRTX) on 20 Oct 2025.
Change
- Previous filing in this sequence was filed on 19 Feb 2025.
- Current net transaction value: +$25,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001756228
Primary reporting owner
ALSTODT LANCE
- Relationship
- President, CEO, COB, Director, 10%+ Owner
- Address
- BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE
- Signature
- /s/ Lance Alstodt
- Signature date
- 17 Oct 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BRTX
transaction
Common Stock
Award
- Transaction value
- $25,000
- Shares
- +15,625
- Change %
- +9.1%
- Price
- $1.60
- Shares after
- 187,497
- Date
- 06 Oct 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BRTX
transaction
Derivative
Warrant
Award
- Transaction value
- $0
- Shares
- +11,719
- Change %
- Price
- $0.000000
- Shares after
- 11,719
- Date
- 06 Oct 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,719
- Exercise price
- $2.75
BRTX
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 293,479
- Date
- 06 Oct 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 293,479
- Exercise price
- $5.08
- Footnotes
- F1
BRTX
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 42,059
- Date
- 06 Oct 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,059
- Exercise price
- $5.08
- Footnotes
- F1
BRTX
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 106,762
- Date
- 06 Oct 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 106,762
- Exercise price
- $2.91
- Footnotes
- F2
BRTX
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 438,596
- Date
- 06 Oct 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 438,596
- Exercise price
- $1.45
- Footnotes
- F3
BRTX
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 791,885
- Date
- 06 Oct 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 791,885
- Exercise price
- $2.46
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The option is currently exercisable.
Footnote F2
The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
Footnote F3
The option vests and becomes exercisable to the extent of 219,298 shares on February 13, 2024 and 219,298 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
Footnote F4
The options vests and becomes exercisable to the extent of 395,943 shares on February 14, 2025 and 395,942 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested.